Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow CORCEPT THERAPEUTICS INC

Get SEC filing alerts via email and in your feed for CORCEPT THERAPEUTICS INC

CORT

CORCEPT THERAPEUTICS INC

About CORCEPT THERAPEUTICS INC

Corcept Therapeutics develops medications that modulate cortisol to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders. Its core products include Korlym and relacorilant for hypercortisolism, with ongoing trials for cancer, liver disease, ALS, and metabolic conditions. The company leverages proprietary cortisol modulators, patents, and strategic collaborations to address unmet medical needs in hormone regulation and cancer therapy.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from CORCEPT THERAPEUTICS INC

1
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports Q1 2026 Financial Results with $164.9M Revenue and $31.8M Net Loss

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports 13% Revenue Growth to $761.4 Million for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports 13.8% Revenue Growth to $207.6 Million in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports 19% Revenue Growth to $194.4 Million in Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports Q1 2025 Financial Results with $157.2M Revenue

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports 40% Revenue Growth to $675M for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
CORCEPT THERAPEUTICS INC Corcept Therapeutics Reports Significant Revenue Growth and Net Income in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments